Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 10/20 | 0.47 |
| ▸ | NPY1R | P25929 | 5/20 | 0.47 |
| ▸ | NPY2R | P49146 | 4/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.47 |
| ▸ | KISS1R | Q969F8 | 5/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CTSH | P09668 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14534853 | 0.90 | NPY4R (0.50) | NPY4RNPY1RNPY2RNPY5RCTSL | |
| SCHEMBL14509088 | 0.89 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL14509067 | 0.89 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL14509165 | 0.89 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL22010066 | 0.86 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL20715015 | 0.86 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL22009523 | 0.86 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL20715010 | 0.86 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL20714935 | 0.85 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL20714938 | 0.85 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105783-A1 | Process for the manufacture of peptide facilitators of reverse cholesterol transport | SIRCAR JAGADISH C | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105783-A1 | Process for the manufacture of peptide facilitators of reverse cholesterol transport | CETP, NPC1L1, SLC10A1 | NPY4R 1630/4885NPY1R 1379/4885NPY2R 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.